Edition:
United Kingdom

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

26.65USD
23 Feb 2018
Change (% chg)

$0.10 (+0.38%)
Prev Close
$26.55
Open
$26.10
Day's High
$27.94
Day's Low
$24.51
Volume
185,670
Avg. Vol
88,346
52-wk High
$37.00
52-wk Low
$3.13

Chart for

About

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $24.57
Shares Outstanding(Mil.): 4.31
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.91 10.66
ROE: -- 16.41 14.30

BRIEF-Catalyst Biosciences Says Public Offering Of 2.94 Mln Common Shares Priced At $34/Share

* CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

13 Feb 2018

BRIEF-Catalyst Biosciences Announces Proposed Public Offering Of Common Stock

* CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

12 Feb 2018

BRIEF-RTW Investments Reports A 5.71 Percent Passive Stake In Catalyst Biosciences

* RTW INVESTMENTS, LP REPORTS A 5.71 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF JAN 26, 2018 Source text: (http://bit.ly/2nDJSqt) Further company coverage:

05 Feb 2018

BRIEF-Catalyst Biosciences Files For Mixed Shelf Of Up To $150 Mln

* CATALYST BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text - http://bit.ly/2F2CQC6 Further company coverage:

22 Jan 2018

BRIEF-Catalyst Biosciences Initiates Phase 2/3 Trial Of Marzeptacog Alfa (Activated)

* CATALYST BIOSCIENCES INITIATES PHASE 2/3 TRIAL OF MARZEPTACOG ALFA (ACTIVATED) FOR PROPHYLAXIS IN HEMOPHILIA A OR B WITH INHIBITORS

04 Jan 2018

BRIEF-Nexthera Capital Reports 5.4 Pct Passive Stake In Catalyst Biosciences

* NEXTHERA CAPITAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF DEC 20 - SEC FILING Source text : (http://bit.ly/2l9OsLV) Further company coverage:

27 Dec 2017

BRIEF-Catalyst Biosciences Announces Pricing Of Public Offering Of Common Stock

* CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

20 Dec 2017

BRIEF-Catalyst Biosciences Announces Proposed Public Offering Of Common Stock

* CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

19 Dec 2017

BRIEF-Catalyst Biosciences Appoints Edward Williams To Its Board

* CATALYST BIOSCIENCES ANNOUNCES APPOINTMENT OF EDWARD WILLIAMS TO ITS BOARD OF DIRECTORS

14 Dec 2017

BRIEF-Catalyst biosciences Q3 loss per share $1.34

* Catalyst Biosciences reports third quarter 2017 operating & financial results and provides corporate update

02 Nov 2017

Competitors

Earnings vs. Estimates